249 results on '"Zhou, Huafeng"'
Search Results
52. Biomass‐Derived Crocodile Skin‐Like Porous Carbon for High‐Performance Microwave Absorption
53. Characterisation and Skin Distribution of Lecithin-Based Coenzyme Q10-Loaded Lipid Nanocapsules
54. Preparation and Characterization of a Lecithin Nanoemulsion as a Topical Delivery System
55. Remaining Useful Life Prediction of Aeroengine Based on Ghost Approach
56. Intelligent Fault Diagnosis Based on Adversarial Domain Adaptive Network
57. Intelligent Fault Diagnosis Based on Dynamic Convolutional Depth Domain Adaptive Network
58. The Pharmacokinetics and Safety of Idelalisib in Subjects With Moderate or Severe Hepatic Impairment
59. Clinical Drug Interaction Profile of Idelalisib in Healthy Subjects
60. A Power Market Nodal Price Forecasting Based on Historical Electricity Price and Unified Dispatch Load
61. Characterisation and Skin Distribution of Lecithin-Based Coenzyme Q10-Loaded Lipid Nanocapsules
62. Preparation and Characterization of a Lecithin Nanoemulsion as a Topical Delivery System
63. A Power Market Nodal Price Forecasting Based on Historical Electricity Price and Unified Dispatch Load
64. Peak-shift Optimization Model and Pricing Strategies of Power Trading System in Bay Area
65. Research on the impact of demand response programs in day ahead market on the oligarchs in the electricity market
66. Utilization of polyacrylamide-thickening agent and aluminum sulfate liquid accelerator for improving early strength of Portland cement.
67. The effect of land use structure on the distribution of soil nutrients in the hilly area of the Loess Plateau, China
68. Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study
69. A hybrid feature selection algorithm combining information gain and genetic search for intrusion detection
70. The advantages of a novel CoQ10 delivery system in skin photo-protection
71. On-line PMU-based transmission line parameter identification
72. The relationships between land use and soil conditions in the hilly area of the loess plateau in northern Shaanxi, China
73. A Smarter Grid Operation: New Energy Management Systems in China
74. Sub‐synchronous torsional interaction with VSC‐HVDC affected by feed‐forward compensations in current controllers
75. PLL effect on subsynchronous torsional interaction with VSC‐HVDC
76. Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)
77. Calculating sequence impedances of transmission line using PMU measurements
78. Influence of diamond-like carbon coatings and micro-texturing on friction and wear of seal interfaces: Experiment and simulation study
79. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
80. Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.
81. Targeting of coenzyme Q10 via d-alpha-tocopheryl polyethylene glycol 1000 succinate-based nanoemulsion to the heart
82. Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study
83. Detection of Escherichia coli with a label-free impedimetric biosensor based on lectin functionalized mixed self-assembled monolayer
84. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
85. Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.
86. Commutation Failure Analysis Considering Direct Current Dynamics in LCC-HVDC Systems
87. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies
88. Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor
89. Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
90. Research and development of Operation Smart System in CSG
91. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
92. Calculating sequence impedances of transmission line using PMU measurements
93. On-line PMU-based transmission line parameter identification
94. Abstract CT204: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
95. Abstract CT217: Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects
96. Abstract 4633: Pharmacokinetics, metabolism and excretion of idelalisib
97. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
98. Drug interaction profile of idelalisib and its major metabolite, GS-563117.
99. A Novel Method for the Improved Skin Whitening Effect Based on Nanostructured Lipid Carrier
100. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.